Higher expression of connexin 40 in human atrial tissue of patients with type 2 diabetes who have undergone a coronary artery bypass graft surgery

Pascal Daleau¹², Geneviève Comeau¹, Dominique Fournier¹, Dany Patoine¹, Patrick Mathieu¹³, Paul Poirier¹²

¹Quebec Heart and Lungs Institute, Laval Hospital Research Centre, Quebec, Canada; pascal.daleau@pha.ulaval.ca
²Faculty of Pharmacy, Laval University, Quebec, Canada
³Faculty of Medicine, Laval University, Quebec, Canada

Received 21 November 2009; revised 13 January 2010; accepted 16 January 2010.

ABSTRACT

Background: Although cardiac-related mortality rates are declining for the general population in the United States, this is not the case for patients with diabetes. Diabetes is a significant independent predictor of atrial fibrillation (AF), the most common cardiac rhythm disturbance responsible for substantial morbidity and mortality. Objectives: This research was designed to evaluate properties of the atrial tissue between patients with and without type 2 diabetes. Heart rate variability (HRV) indices were calculated and expression of Kv1.5, connexin 43 (Cx43), and 40 (Cx40) were compared. Methods: Patients undergoing a CABG were enrolled: 10 with type 2 diabetes and 8 without diabetes, paired for age, gender and co-morbidities such as hypertension and dyslipidemia. All patients showed normal ejection fraction. A sample of right auricular appendix was taken during CABG and Kv1.5, Cx40 and Cx43 protein contents were determined by western blotting and normalized to α-tubulin level. Results: No HRV difference was found between patients with and without diabetes. Cx43 and Kv1.5 levels were unaffected by diabetes (p=0.20 and 0.07, respectively) whereas Cx40 content was significantly increased by 55% (p=0.02). Levels of Cx43 phosphorylated and non-phosphorylated forms were non-significantly decreased in patients with diabetes. Conclusion: Patients with type 2 diabetes had higher expression of Cx40 in the right auricular appendix tissue. In light of other studies having demonstrated a link between AF and Cx40 expression, it is possible that higher prevalence of AF in patients with diabetes is explained, at least partially, by differential expression of gap-junction proteins.

Keywords: Diabetes; Gap Junctions; Atrial Tissue; Atrial Fibrillation

1. INTRODUCTION

The prevalence of diabetes is steadily increasing in westernized societies as well as in developing countries. Although the overall cardiac-related mortality rate has been declining for the general population in the United States, this is not the case for patients with diabetes [1]. Of particular significance, diabetes is a risk factor for different heart-related conditions such as coronary artery disease, heart failure, aortic stenosis and arrhythmias [2].

Atrial fibrillation (AF) is the most common arrhythmia and is responsible for substantial morbidity and mortality [3]. In the Framingham study, systemic hypertension and diabetes were found to be independent predictors of AF [4]. For men and women, respectively, diabetes increased by 1.4 and 1.6 fold the risk of developing AF. The risk of developing AF correlates with atrial dilatation, and the presence of left ventricular diastolic dysfunction [5]. Since AF occurs as an ongoing process over time, subtle atrial abnormalities may precede overt atrial dilatation and contractile dysfunction [5-7]. These could be linked to alterations in electrophysiological properties predisposing to AF.

In animal models (mostly streptozotocin-induced diabetes models), diabetes mellitus is responsible for cardiac arrhythmias, probably caused by an excessive lengthening of the cardiac action potential [8]. Several changes in ionic currents have been described in cardiomyocytes isolated from animal models of diabetes, principally a decrease in the transient repolarizing potassium current I₉ [8,9]. This effect could possibly be partially mediated by impaired sympathetic nervous system...

It should be pointed out that a reduction in $V_{\text{max}}$ [12] the maximum speed of the rising phase of the action potential, and a prolongation of the QRS complex [13, 14] have been associated with diabetes. Changes in the intercellular electrical coupling through gap junctions could be involved in this effect. Indeed, it was demonstrated that elevated glucose concentrations inhibit gap junction intercellular communication and reduced connexin (Cx) expression in a variety of cells including vascular smooth muscle cells, endothelial cells, and retinal microvessels. It has been proposed that high glucose concentration interfered with gap junction through the activation of protein kinase C [15-18]. In addition, it has been reported in rat model of diabetes that a down-regulation of Cx43 occurred and is associated with a compensatory over-expression of other Cxs [19,20]. However, direct alteration of gap junctions by diabetes were never assessed in human cardiomyocytes.

The purpose of this study was to evaluate properties of the atrial tissue between patients with and without type 2 diabetes. Heart rate variability (HRV) indices were calculated to evaluate the potential influence of the cardiac autonomic nervous system. Expression levels of Kv1.5 (underlying $I_{\text{Kur}}$), connexin 43 (Cx43), and 40 (Cx40) were compared between patients with and without type 2 diabetes.

2. RESEARCH DESIGN AND METHODS

2.1. Study Design

Ten subjects with type 2 diabetes and 8 subjects without diabetes undergoing a coronary artery bypass grafting surgery (CABG) were enrolled in this study. Patients in sinus rhythm aged between 35 and 70 were included. Patients with and without type 2 diabetes were paired for age, gender, co-morbidities such as hypertension and dyslipidemia. All patients had to show normal ejection fraction. Exclusion criteria were: 1) previous history of supraventricular arrhythmia, 2) significant hepatic or renal dysfunction (creatinine >150 mmol/L), 3) significant pulmonary or thyroid disease, 4) any connective tissue disease or history of malignancy, 5) episode of recent heart failure, 6) acute coronary syndrome within the last 3 months and, 7) smoking within the previous 3 months. The present study was approved by the local ethical committee of Laval Hospital.

A sample of right auricular appendix was taken at the beginning of the CABG procedure, and immediately placed in an oxygenated Tyrode solution (in mM: NaCl 137, KCl 5.4, CaCl$_2$ 1.8, MgCl$_2$ 1, NaHCO$_3$ 12, NaH$_2$PO$_4$ 0.4, glucose 5.6) at 4°C. The tissue was subsequently immersed in liquid nitrogen and stored at -80 °C for western analyses.

2.2. Heart Rate Variability

Heart rate variability (HRV) was derived from a 24-hour Holter monitoring system (Marquette Electronics Inc., Milwaukee, WI) in all subjects during normal daily life activity. HRV derived from 24-hour ambulatory monitoring is reproducible and free of placebo effect [21]. Using frequency domains, power in the low frequency (LF, 0.04-0.15 Hz) that is an index of both sympathetic and parasympathetic activity, and high frequency (HF, 0.15-0.4 Hz) that is an index of solely parasympathetic activity, were calculated. LF/HF ratio is the power in low frequency divided by the power in high frequency. Using time domains, the standard deviation of the RR intervals (SDNN), the square root of the mean squared differences of successive RR intervals (rMSSD) and the standard deviation of the average RR intervals calculated over 5-min periods (SDANN) were determined. pNN50 is the proportion of interval differences of successive NN intervals greater than 50 ms. NN intervals are the normal-to-normal intervals that include all intervals between adjacent QRS complexes resulting from sinus node depolarizations in the entire 24-hour ECG recording as previously reported [7].

2.3. Protein Isolation and Western Blot Analysis [22,23]

Total protein content was determined with bovine serum albumin as standard and subsequently separated with an 8% denaturing-PAGE. Proteins transferred to Immobilon PVDF membranes were incubated with antibodies for Kv1.5 [Alomone Labs], Cx40 [Chemicon Int.] (polyclonal, raised in rabbit) and Cx43 [Chemicon Int.] (monoclonal, mouse). Epitopes are residues 513-602 of mouse Kv1.5, gap junction alpha-5 protein of mouse connexin 40 [CxA-5], and residues 252-270 of native connexin 40 

Copyright © 2010 SciRes  
Openly accessible at http://www.scirp.org/journal/HEALTH/
groups were performed using an unpaired Student’s t-test and a p value<0.05 was considered significant.

3. RESULTS

There was no difference in age, body mass index (BMI) and left ventricular ejection fraction between groups (Table 1). As expected, fasting glucose level was significantly higher in patients with diabetes (Table 1). There were no differences in the lipid profile between groups. Also, drug regimen was comparable between groups except for the use of hypoglycaemic agents in patients with diabetes (Table 2). Results from the 24-hour Holter analysis, showed no significant difference in the indices assessed (LF, HF, LF/HF ratio, SDANN, rMSSD, pNN50, mean NN, SDNN) between patients with and without diabetes.

Densitometric analysis showed that Cx43 levels (normalized with α-tubulin and tested in triplicate) were unaffected by diabetes (Figure 1, p = 0.20). When compared to control subjects, patients with diabetes had a tendency of having higher expression of Kv1.5 (Figure 3, p=0.07), whereas Cx40 content was significantly increased by 55% (Figure 2, p=0.02). We also assessed expression levels of phosphorylated forms of Cx43. In patients with diabetes, expression levels of the two phosphosioforms of Cx43 (P2 and P1) were decreased to 71% and 64% of control values respectively. The non-phosphorylated form of Cx43 (P0) decreased to 79% of control values. However, these differences were not significant for all isoforms (p = 0.46, 0.21 and 0.23 respectively for P0, P1 and P2).

Among patients with diabetes, 50% (5/10) developed new onset of postoperative AF significant enough (episodes longer than 2h or recurrent episodes of AF) to require pharmacological treatment compared to 25% (2/8) in the control group (p = 0.27).
### Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Diabetes (n=10)</th>
<th>Controls (n=8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61.5 ± 13.1</td>
<td>68.4 ± 6.7</td>
<td>0.197</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>34.1 ± 7.5</td>
<td>29.5 ± 4.4</td>
<td>0.198</td>
</tr>
<tr>
<td>EF (%)</td>
<td>57.3 ± 7.1</td>
<td>63.4 ± 8.7</td>
<td>0.065</td>
</tr>
<tr>
<td>Men/Women</td>
<td>7/3</td>
<td>7/1</td>
<td>0.815</td>
</tr>
</tbody>
</table>

**Blood analysis:**

<table>
<thead>
<tr>
<th></th>
<th>Diabetes (%)</th>
<th>Controls (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mmol/L)</td>
<td>7.2 ± 1.6</td>
<td>5.2 ± 0.6</td>
<td>0.003</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.1 ± 1.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Apo B (g/L)</td>
<td>0.71 ± 0.18</td>
<td>0.86 ± 0.21</td>
<td>0.148</td>
</tr>
</tbody>
</table>

**Lipid profile:**

<table>
<thead>
<tr>
<th></th>
<th>Diabetes (mmol/L)</th>
<th>Controls (mmol/L)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>3.54 ± 0.62</td>
<td>4.04 ± 0.81</td>
<td>0.160</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.72 ± 0.87</td>
<td>1.82 ± 0.99</td>
<td>0.756</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.11 ± 0.14</td>
<td>1.18 ± 0.27</td>
<td>0.657</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>1.65 ± 0.48</td>
<td>2.03 ± 0.50</td>
<td>0.120</td>
</tr>
<tr>
<td>Total-C/HDL-C</td>
<td>3.20 ± 0.58</td>
<td>3.57 ± 1.08</td>
<td>0.372</td>
</tr>
</tbody>
</table>

BMI = Body mass index; EF = Ejection fraction

### Table 2. Co-morbidities and drug regimen in both groups.

<table>
<thead>
<tr>
<th></th>
<th>Diabetes (n=10)</th>
<th>Controls (n=8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>70 (7)</td>
<td>62.5 (5)</td>
<td>0.107</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>70 (7)</td>
<td>75 (6)</td>
<td>1.000</td>
</tr>
<tr>
<td>Smoking</td>
<td>10 (1)</td>
<td>37.5 (3)</td>
<td>1.000</td>
</tr>
</tbody>
</table>

**Rx Classes**

<table>
<thead>
<tr>
<th></th>
<th>Diabetes (%)</th>
<th>Controls (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerin</td>
<td>40 (4)</td>
<td>50 (4)</td>
<td>0.143</td>
</tr>
<tr>
<td>β-blockers</td>
<td>90 (9)</td>
<td>87.5 (7)</td>
<td>1.000</td>
</tr>
<tr>
<td>CCB</td>
<td>50 (5)</td>
<td>50 (4)</td>
<td>1.000</td>
</tr>
<tr>
<td>ACEI</td>
<td>30 (3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ARB</td>
<td>60 (6)</td>
<td>12.5 (1)</td>
<td>1.000</td>
</tr>
<tr>
<td>α1 inhibitors</td>
<td>10 (1)</td>
<td>12.5 (1)</td>
<td>1.000</td>
</tr>
<tr>
<td>ASA</td>
<td>90 (9)</td>
<td>87.5 (7)</td>
<td>0.125</td>
</tr>
<tr>
<td>Diuretics</td>
<td>40 (4)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Statins</td>
<td>90 (9)</td>
<td>62.5 (5)</td>
<td>0.375</td>
</tr>
<tr>
<td>Fibrates</td>
<td>-</td>
<td>12.5 (1)</td>
<td>-</td>
</tr>
<tr>
<td>Oral hypoglycemic agents</td>
<td>100 (10)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Benzodiazepine</td>
<td>10 (1)</td>
<td>25 (2)</td>
<td>1.000</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>10 (1)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### 4. DISCUSSION

This study assessed the effects of type 2 diabetes on the expressions of connexins and Kv1.5 in the human heart. The most important finding of this work is that patients with type 2 diabetes had significantly higher expression of Cx40 in the right auricular appendix tissue. Apart from the diabetic status, the 2 groups were well matched in terms of age and risk factors, implying that the observed modulation of connexin is likely to reflect the effect of diabetes per se.

#### 4.1. Expression of Connexins and Modulation by Diabetes

Assessment of protein content revealed that when compared to control patients, the level of Cx40 in the right auricular appendix specimens was increased by 55 % in individuals having type 2 diabetes. Similarly, a recent study in rats with streptozotocin-induced diabetes has shown that expression of Cx40 was increased in retinal microvessels [18]. Although not statistically significant, we also observed a trend toward a decreased expression of Cx43 in the right auricular appendix tissues of pa-
patients with type 2 diabetes. All isoforms of Cx43 (the two phosphoisoforms and the non-phosphorylated form), were diminished, although non-significantly. It should be emphasized that in diabetic animal models a reduction in the expression of Cx43 has been documented in several tissues [17,24,25], including the heart [18,26], though exceptions also exist [27,28].

In one study, while a down-regulation of Cx43 was demonstrated in retinal microvessels of diabetic rats, an over-expression of Cx40 and Cx45 were found [18]. Thus, it seems possible that a down-regulation of one type of connexin is offset by the increased production of another type of gap junction protein. In the same line, a recent study analyzing the expression of connexins in the bladder of diabetic rat reported a lower amount of Cx43 isoform and higher expression of Cx32 and 26 [17]. However, it has been stressed that the function of one type of connexin cannot necessarily be restored by the presence of another but different member of the connexin family [29]. Hence, this ‘replacement’ hypothesis certainly deserves more investigations.

4.2. Atrial Fibrillation, Connexins and K+ Channels

Diabetes has been reported as a strong and independent risk factor for the development of AF [30,31]. Of note, episodes of postoperative AF have been associated to a higher expression Cx40 in the right auricular appendix obtained from patients undergoing cardiac surgery [32,33,34,35]. It is likely that the relative abundance of Cx43 and Cx40 plays an important role in the atrial impulse propagation, and whereby dominance of Cx40 decreases local propagation velocity [36]. Therefore, the modulation of Cx40 expression by the diabetic environment could lead to micro-heterogeneities of electrical conduction pattern, promoting by this way episodes of AF.

In different studies with experimental animal models, the activity of several cardiac potassium currents, such as Ito, IK and Ibar, are modulated by diabetes and are possibly involved in the development and/or maintenance of AF [37,38,39]. However, the present results in human right auricular appendix tissue show that Kv1.5 expression remains unchanged in patients with diabetes, suggesting that Ibar is not affected. Nevertheless, one cannot exclude a direct modulation of this current by glucose and/or insulin levels.

4.3. Clinical Implications

AF is the most frequent arrhythmia and has been linked to aging as well as to diabetes. While atrial remodeling is undoubtedly an important process participating to the development and the maintenance of AF, an electrophysiological substrate is actively involved in the generation of arrhythmia. In this regard, the dispersion of atrial refractoriness and the ensuing development of multiple reentry wavelets are likely to be important underlying mechanisms pertaining to AF. In this study, the finding of a significant modulation of Cx40 in patients with diabetes may partly explain the well-documented association between diabetes and AF. By which mechanism diabetes contributes to increase Cx40 expression in atrial tissue is still unknown, but it is possible that inflammatory and/or oxidative stress pathways [40,41], which are incidentally activated in subjects with diabetes, may contribute to modify the amount of connexins in atrial cardiomyocytes.

4.4. Limitations

Insofar patients in the present study had significant coronary artery disease and other co-morbidities, the present findings cannot be inferred to the overall spectrum of patients with diabetes. Particularly, pre-diabetic subjects with glucose intolerance were not studied and may have given further insights as to whether the observed modifications may occur at an earlier stage. In addition, the size of the left atria, which represent atrial remodeling, was not documented in the present study. However, the effect of atrial remodeling, a possible confounding variable, was minimized by having selected a cohort of patients without significant valve disease, a normal ejection fraction, and in sinus rhythm.

4.5. Conclusions

In conclusion, we found an up-regulation of Cx40 protein content in right auricular appendix tissue from patients with type 2 diabetes. In light of other studies having demonstrated a link between AF and Cx40 expression, it is possible that higher prevalence of AF in patients with diabetes is explained, at least partially, by differential expression of gap-junction proteins. Albeit further studies are still needed to understand the full implication of Cx40 in AF, this study casts some light on a potentially important process occurring in individuals with diabetes, and may open-up new therapeutic and/or research vistas in order to treat and/or prevent AF in this at-risk population.

5. ACKNOWLEDGEMENTS

Drs Paul Poirier and Patrick Mathieu are research scholars from the Fonds de la Recherche en Santé du Québec. This work was supported by operating grants from the Quebec Heart Institute (Drs Paul Poirier and Pascal Daleau) and the Heart and Stroke Foundation of Quebec (Dr Pascal Daleau).

REFERENCES


